Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Avirup Guha; Merna Armanious; Michael G. Fradley

doi:10.1016/j.tcm.2018.06.001

Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Avirup Guha, Merna Armanious, Michael G. Fradley

Cardiology

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Abstract

There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.

Original language	English (US)
Pages (from-to)	29-39
Number of pages	11
Journal	Trends in Cardiovascular Medicine
Volume	29
Issue number	1
DOIs	https://doi.org/10.1016/j.tcm.2018.06.001
State	Published - Jan 1 2019

Keywords

Cardio-oncology
Cardiotoxicity
Proteasome inhibitors
Tyrosine kinase inhibitors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.tcm.2018.06.001

Cite this

@article{5f4dd61cdb1f4747a3f21df8d9d46634,

title = "Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities",

abstract = "There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.",

keywords = "Cardio-oncology, Cardiotoxicity, Proteasome inhibitors, Tyrosine kinase inhibitors",

author = "Avirup Guha and Merna Armanious and Fradley, {Michael G.}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.tcm.2018.06.001",

language = "English (US)",

volume = "29",

pages = "29--39",

journal = "Trends in Cardiovascular Medicine",

issn = "1050-1738",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

AU - Guha, Avirup

AU - Armanious, Merna

AU - Fradley, Michael G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.

AB - There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies.

KW - Cardio-oncology

KW - Cardiotoxicity

KW - Proteasome inhibitors

KW - Tyrosine kinase inhibitors

UR - https://www.mendeley.com/catalogue/dc71bbc0-fb5a-3715-9592-d42e20c5207c/

U2 - 10.1016/j.tcm.2018.06.001

DO - 10.1016/j.tcm.2018.06.001

M3 - Article

C2 - 29910109

SN - 1050-1738

VL - 29

SP - 29

EP - 39

JO - Trends in Cardiovascular Medicine

JF - Trends in Cardiovascular Medicine

IS - 1

ER -

Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this